https://www.selleckchem.com/products/iacs-010759-iacs-10759.html But the patient refused chemotherapy, and only treated with "DXM+VP-16" to control hemophagocytic syndrome, and unfortunately died due to the disease progression. Cutaneous involvement in diffuse large B-cell lymphoma and hemophagocytic syndrome patients with first presentation of dermatomyositis is relatively rare. Malignacy screening should be performed as soon as possible after newly diagnosed DM, so that the patient can get early diagnosis and effective treatment to improve survival rate. Cutaneous involvement in diffuse large B-cell lymphoma and hemophagocytic syndrome patients with first presentation of dermatomyositis is relatively rare. Malignacy screening should be performed as soon as possible after newly diagnosed DM, so that the patient can get early diagnosis and effective treatment to improve survival rate. To study the impact of anticoagulant to the quality of umbilical cord blood (UCB). 6060 cord blood units (CBUs) were classified into five groups, such as 28 ml (10-29) ml, 28 ml (30-69) ml, 28 ml (70-109) ml, 28 ml (110-150) ml and 28 ml (>150) ml according to volume ratio of anticoagulant and CBVs. The count of pre-cryopreservation total nucleated cell (pre-TNC), the viability of nucleated cell (VNC), the amount of CFU-GM and the ratio changes of CD34 were evaluated and analyzed statistically. It was found that pre-TNC increased with the growth of volume of CBUs (r=0.9937) under the certain volume of antico-agulant, and the TNC in the minimum UCB volume group was (2.57±0.89)×10 ; the VNC grew up with the increasing count viability of volume (r=0.9897), and the average viability of the minimum volume group remained over 95%; the CFU-GM climbed up with the increasing of volume (r=0.9024), and the number of CFV-GM in minimum volume group reached to of 89/×10 ; CD34 % grew up with the increase of volume of CBUs (r=0.9641), and the ratio was (0.30±0.19)% for the minimum volume group. In ce